IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This study is for patients with EFGR gene sensitive mutations diagnosed by pathology or
cytology, having a course of chest radiotherapy treatment and molecular Target Therapy for
the treatment of stage IV non-small cell lung cancer. Patients with non-small cell lung
cancer have a risk of the tumour in the lung recurring or progressing after treatment.
In this study, the investigators aim to verify the following hypothesis:
- whether in combination with concurrent or concomitant EGFR-TKI regimen chemotherapy,
Intensity Modulated Radiation Therapy can reduce the risk of the tumour in the lung
recurring or progressing similarily.
- Intensity Modulated Radiation Therapy concomitant with EGFR-TKI has a better normal
tissue dose/volume tolerance than concurrent regimen.
- the survival can be improved by using this new molecular Target-radiotherapy method.